



## NEWS RELEASE

### **LAWSUIT AGAINST TRT DROPPED!**

**October 31, 2007 (Woodstock, Georgia)** – Tissue Regeneration Technologies (TRT) is pleased to announce that the intellectual property lawsuit filed by Sanuwave, Inc. against TRT was dismissed *with prejudice*. This dismissal means that the subject claims, or similar claims, cannot be raised again by Sanuwave, Inc. TRT believes that this dismissal is not only a great victory for TRT's patent pending Soft Focused technology but also for the shockwave industry as a whole.

“We feel this dismissal vindicates TRT and its officers and physician partners. The allegations questioning the honesty and character of TRT and our physician partners were without merit. Our physician partners, as major contributors to the formation of the shockwave industry, are honest and well respected throughout the community and shockwave industry. Any knowledgeable participant in the shockwave industry would know that our physician partners' reputations are beyond reproach and any 'litigation strategy' challenging their reputations would fail. The shockwave industry rallied to the defense of our physician partners and TRT, and for this we are forever thankful” stated John Warlick, TRT's President and CEO.

TRT can now re-double its efforts on proving the safety and efficacy of its Soft Focus technology for tissue regeneration for the benefit of patients, payors, and physicians.

#### **About TRT**

TRT is conducting FDA trials with its DermaGold™ device for the treatment of wounds as well as plantar fasciitis. The FDA cleared TRT's LithoGold™ lithotripsy system marketed for the treatment of kidney and ureteral stones. Our devices are currently CE approved and distributed in approximately 20 countries throughout North America, Europe, Asia, Africa and South America.

TRT's state-of-the-art medical devices utilize MultiWave™ technology (a combination of heat, electromagnetic, acoustic, and light energies: h-e-a-l) to provide non-invasive treatment for numerous pathological conditions, including chronic wounds, multiple periodontal applications, pseudoarthrosis and other avascular conditions of the bone, and ischemic heart disease. TRT is headquartered in Woodstock, Georgia from which TRT operates its urology division, Shockwave Technical Service, and cardiac subsidiary, Cardiac Regeneration Technologies, LLC. Production of TRT's devices is handled by its manufacturing subsidiary, MTS Europe GmbH, located in Lake Constance, Germany.

For more information, please visit the company's website at [www.trtllc.com](http://www.trtllc.com).

*Contact Information:* Julie Dodd, (770) 966-1315 / [jdodd@trtllc.com](mailto:jdodd@trtllc.com)